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Irreversible N -methyl-D-aspartate receptor (NMDAR) antagonism is known to provoke
symptoms of psychosis and schizophrenia in healthy humans. NMDAR hypofunction is
believed to play a central role in the pathophysiology of both disorders and in an animal
model of psychosis, that is based on irreversible antagonism of NMDARs, pronounced
deﬁcits in hippocampal synaptic plasticity have been reported shortly after antagonist
treatment. Here, we examined the long-term consequences for long-term potentiation
(LTP) of a single acute treatment with an irreversible antagonist and investigated whether
deﬁcits are associated with memory impairments. The ability to express LTP at the
perforant pathway – dentate gyrus synapse, as well as object recognition memory was
assessed 1, 2, 3, and 4 weeks after a single treatment of the antagonist, MK801. Here,
LTP in freely behaving rats was signiﬁcantly impaired at all time-points compared to
control LTP before treatment. Object recognition memory was also signiﬁcantly poorer in
MK801-treated compared to vehicle-treated animals for several weeks after treatment.
Histological analysis revealed no changes in brain tissue. Taken together, these data
support that acute treatment with an irreversible NMDAR-antagonist persistently impairs
hippocampal functioning on behavioral, as well as synaptic levels. The long-term deﬁcits
in synaptic plasticity may underlie the cognitive impairments that are associated with
schizophrenia-spectrum disorders.
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INTRODUCTION
The uncompetitive N-methyl-D-aspartate (NMDA) receptor
antagonist, MK801, is frequently used in neuroscientiﬁc research.
Its unique kinetics and ability to induce all kinds of schizophre-
nia symptoms in humans (Krystal et al., 1994; Lahti et al., 2001)
has promoted it into one of the drugs of choice in modeling
schizophrenia in animals (Rujescu et al., 2006). Acute treat-
ment with MK801 is believed to efﬁciently mimic a single acute
psychosis-like episode in rats that may emulate ﬁrst-episode psy-
chosis (Kehrer et al., 2007; Wöhrl et al., 2007; Manahan-Vaughan
et al., 2008a). Despite its immediate effects, however, it also
induces long-lasting dysfunctions, speciﬁcally within the cogni-
tive domain. For example, long-lasting impairments in spatial
learning in rodents after a single MK801-treatment that per-
sisted for up to months have been reported (Wozniak et al.,
1996; Lukoyanov and Paula-Barbosa, 2000; Manahan-Vaughan
et al., 2008a,b). Furthermore, it has been shown that a single
Abbreviations: ANOVA, analysis of variance; DG, dentate gyrus; EC, entorhinal
cortex; fEPSP, ﬁeld excitatory postsynaptic potential; GlyT1, glycine transporter-1;
HFS, high frequency stimulation; i.p., intraperitoneal; LTP, long-term potentiation;
NMDA, N-methyl-D-aspartic acid or N-methyl-D-aspartate; NMDAR, N-methyl-
D-aspartic acid or N-methyl-D-aspartate receptor; ORT, object recognition task;
PCP, phencyclidine; PDE4, phosphodiesterase 4; PS, population spike; RSC, retro-
splenial cortex; ROI, region of interest; T1, trial 1; T2, trial 2; TMS, transcranial
magnetic stimulation.
injection of MK801 to rats results in short-lasting transient
behavioral aspects of psychosis-related behavior that may emu-
late ﬁrst-episode psychosis (Wöhrl et al., 2007; Manahan-Vaughan
et al., 2008a,b).
All of the abovementioned effects are hippocampus-related.
Indeed, the hippocampus is one of the brain structures that is
most severely affected in schizophrenia pathology. The hippocam-
pus is therefore considered to be a signiﬁcant element in the
development of schizophrenia (Harrison, 2004). NMDA recep-
tor hypofunction is proposed to contribute importantly to the
development and progress of schizophrenia (Lindsley et al., 2006).
A key question in this possibility is whether the prolonged deﬁcits
in hippocampus-dependent memory that are triggered by treat-
ment with an irreversible NMDAR-antagonist, such as MK801,
are accompanied by deﬁcits in synaptic plasticity. In the present
study, we explored whether the loss of long-term potentiation
(LTP) triggered by NMDAR antagonism in this animal model of
psychosis persists for long periods, as a clue to the substrate for
disturbed cognition as the disease develops. In line with this, we
also evaluated cognitive behavior.
Our main goal was to gain insight into the long-term patho-
physiology that might develop as a consequence of an acute
psychosis-like episode. We found enduring deﬁcits in the ability to
express hippocampal LTP 1, 2, 3, and 4 weeks after a single treat-
ment with MK801. Object recognition memory was also impaired
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for several weeks. Thus, a single treatment with MK801 impairs
hippocampal functioning in a long-lasting way on behavioral, as
well as synaptic levels, whereby the long-term deﬁcits in synaptic
plasticity may underlie the cognitive impairments.
The persistent change in hippocampal functioning after an
acute MK801-induced psychosis-like event may be involved into
the mechanisms that contribute to the progression of ﬁrst-episode
psychosis into chronic schizophrenia. We hypothesize that the
enduring long-term deﬁcit in the ability to express synaptic plas-
ticity and to engage in object recognition memory that occurs in
MK801-treated rats may reﬂect chronic changes in hippocampal
function related to psychosis and that the disturbance in synap-
tic plasticity may contribute to the increased vulnerability of the
brain for further schizophreniform episodes.
MATERIALS AND METHODS
ETHICAL STANDARDS
The present study was carried out in accordance with the Euro-
pean Communities Council Directive of September 22nd, 2010
(2010/63/EU) for care of laboratory animals and after approval of
the local ethic committee (senate of Berlin or Bezirksamt Arns-
berg). All efforts were made to reduce the number of animals
used.
EXPERIMENTAL ANIMALS
Seven- to eight-week-old male Wistar rats (Charles River, Ger-
many), were housed on a 12-h light/12-h dark cycle (lights on
at 07:00 AM) for at least 1 week after their arrival in the animal
facility before treatment or surgery.
Surgical implantations
Animals were anesthetized (52mg/kg pentobarbital via intraperi-
toneal injection, i.p.) and underwent chronic implantation of
electrodes in the granule cell layer of dentate gyrus (DG) that
is part of the hippocampal formation. A monopolar recording
electrode (1 mm diameter, 3.1 mm posterior to bregma, 1.9 mm
lateral to the midline) and a bipolar stimulating electrode in the
perforant pathway (1 mm diameter, 6.9 mm posterior to bregma,
4.1 mm lateral to the midline) were inserted. The animals were
allowed between 7 and 10 days to recover from surgery before
experiments were conducted.
Evoked ﬁeld potential recordings
Throughout all experiments, the animals could move freely within
the recording chamber (40 cm × 40 cm × 40 cm) and had
free access to food and water. For acclimatization the animals
were transferred to the experiment room 1 day in advance. The
implanted electrodes were connected through a head stage by a
ﬂexible cable and a swivel connector to the stimulation unit and
ampliﬁer. Recordings were stored on a personal computer.
Responses were evoked by stimulating at low frequency
(0.025 Hz, 0.2 ms stimulus duration, 10,000 Hz sample rate).
For each time-point, ﬁve evoked responses were averaged. DG
population spike (PS) amplitude, as well as ﬁeld excitatory post-
synaptic potential (fEPSP) slope were monitored: PS amplitude
reﬂects summated actionpotentials from the somatic layer of gran-
ule cells in the DG,whereas alterations of fEPSP indicate dendritic
changes. Each experiment startedwith an input-output (i/o) curve
(maximal stimulation 900μA) to determine the stimulus intensity
required to elicit a PS that was of 40% of the maximum obtained
in the i/o curve. The i/o-curves between vehicle- and MK801-
treated animals did not differ at any time-point after treatment. To
ensure stability of recordings and to assess basal synaptic transmis-
sion, all animals were tested in a baseline experiment ﬁrst, where
only test-pulse stimulation was applied. LTP was induced by high-
frequency stimulation (HFS; 10 bursts of 15 pulses at 200 Hz with
10 s interburst interval) and was recorded 1 week before (pre-
treatment LTP control) and 1, 2, 3, and 4 weeks after MK801-
or vehicle-treatment. PS and fEPSP slope values for pretreatment
LTP did not differ signiﬁcantly in between the two experimen-
tal groups. At the beginning of each LTP experiment baseline PS
amplitude was obtained by averaging the response to stimulation
(ﬁve sweeps at 40 s intervals), every 5 min over a period of 60 min.
At this point HFS was given, and three additional measurements
at 5 min intervals were taken, followed by recordings at 15 min
intervals for 24 h.
Histology
At the end of the electrophysiological study, brains were removed
and histological veriﬁcation of electrodes and cannula localization
was carried out. Brain sections (16 μm) were stained according
to the Nissl method using 1% toluidine blue and then examined
using a light microscope. Brains, in which an incorrect electrode
or cannula localization was found, were discarded from the study.
Quantitative analysis of neuron numbers
Male Wistar rats (7–8 weeks old) were treated with either MK801
(mg/kg) or saline. 4 weeks after injection with vehicle (n = 5) or
MK801 (n = 5), the animals underwent cardiac perfusion to ﬁx
the brain tissue, as described elsewhere (Naie et al., 2006). Fixed
brains were removed immediately after perfusion and sliced coro-
nally. Brain sections (30 μm) were stained according to the Nissl
methodusing 1% toluidine blue. Image acquisitionwas performed
using a light microscope (Zeiss Axioskop, Zeiss, Germany) with a
100 × objective. Plane −5.3, with respect to Bregma (coordinates
fromPaxinos andWatson,2007),was considered representative for
the three regions of interest (ROIs) – retrosplenial cortex (RSC;
layer IV), DG (somatic layer of the upper blade) and entorhi-
nal cortex (EC; layer II) within each hemisphere as indicated in
Figure 5A. Cell counting of viable neuronswithin predeﬁned areas
of the same size (750 μm × 1000 μm) was carried out using the
Image J software by a treatment-blind investigator.
BEHAVIORAL EXPERIMENTS
Open ﬁeld
The open ﬁeld test was performed 1 week after MK801 or vehicle
treatment in order to assess general locomotor activity of both
groups. For this, the animal was placed in an empty gray square
polyvinyl chloride arena (80 cm × 80 cm × 80 cm) for 5 min.
The light intensity was kept constantly low (5 lux). An automated
TSEVideoMot2-Video activity tracking system (TSE Systems, Bad
Homburg, Germany) tracked the animal’s path. “Total distance
traveled”was assessed as an indicator of locomotor activity and“%
of time spent in center” was assessed as an indicator for anxiety-
related behavior.
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Object recognition task
The object recognition task (ORT) was performed as described
elsewhere (Prickaerts et al., 2002). The apparatus consisted of a
gray square polyvinyl chloride arena (80 cm × 80 cm × 80 cm).
The test was performed with a constant light intensity of 18 lux.
Two different kinds of objects were used: a black polyvinyl rect-
angle tower (9 cm × 11 cm × 23 cm) and a transparent glass
cylinder (10 cm diameter, 30 cm height). The objects could not be
displaced by the animals, as they were weighted down (internally)
with sand or stones.
Three habituation sessions preceded the test, in which the ani-
mals were allowed to explore the empty arena for 5 min each on
three preceding days. The testing was carried out directly after the
last habituation session. The testing comprised two trials of 3 min
duration each. A rat was always placed into arena facing themiddle
of the front wall. During the ﬁrst trial (T1) an animal was allowed
to explore two identical objects, which were placed symmetrically
20 cm away from the walls. After T1 the rat was put back into its
home cage. 4 h later the second trial (T2) took place, in which
the rat was placed back into the arena and exposed to a familiar
and a novel object. The testing session was videotaped. The times
spent exploring each object during T1 and T2 were scored manu-
ally. Exploration was deﬁned as directing the nose to the object at a
distance of no more than 2 cm and/or touching the object with the
nose. Sitting on the object was not considered exploratory behav-
ior. In order to avoid the presence of olfactory cues the objects
and the arena were always thoroughly cleaned with 70% ethanol
and then washed with water before each trial. Furthermore, as
the objects were available in triplicate, neither of the two identical
objects from T1 had to be reused in T2. All combinations and loca-
tions of objects were used in a balancedmanner to reduce potential
biases, such as preferences for particular locations or objects. The
testing order was determined randomly. Rats that did not explore
the objects at all in any trial were removed from analysis.
Compounds and drug treatment
The NMDA receptor antagonist [+]-5-methyl-10,11-dihydro-
5Hdibenzo-[a,d]-cyclohepten-5,10-imine hydrogen maleate
(MK801, Tocris, Germany) was dissolved in 0.9% physiologi-
cal saline. MK801 (5 mg/kg) or vehicle (10 ml/kg) were injected
intraperitoneally (i.p.) 7 days before commencement of ﬁrst exper-
iments. The concentration of MK801 was chosen in accordance
with previous studies (Wöhrl et al., 2007; Manahan-Vaughan et al.,
2008a,b), in which the same dose proved to be effective in inducing
long-lasting effects. A single high-dose treatment, as opposed to
chronic low-dose treatment, was chosen in order to model exclu-
sively the very ﬁrst acute psychosis-related experience. Directly
after injection, acute transient psychosis-like behaviors (locomo-
tion, ataxia, and stereotypy) were scored as described elsewhere
(Wöhrl et al., 2007) in order to evaluate the effectiveness of the
treatment.
DATA ANALYSIS
In all electrophysiological experiments, data were expressed as
mean % pre-injection values ± standard error of the mean.
ANOVA with repeated measures was used to evaluate differ-
ences between pretreatment control experiments and experiments
after MK801 or vehicle application. Therefore, all values after
stimulation (HFS) were compared. In the open ﬁeld study, one-
way ANOVA was used to assess the differences in total distance
moved and in percentage of time spent in center between the con-
trols and MK801-treated animals. In the ORT, percentage of total
exploration time for each object during T1 and T2 were calculated.
T-test for independent samples was used in order to analyze time
spent exploring the familiar as compared to the new object for
every time-point. Differences in total exploration times in T1 and
T2 were analyzed via a one-way ANOVA. Statistical analysis was
performed using the SPSS software (version 19). Cell counts have
been analyzed using a two-way ANOVA (treatment × area). The
level of signiﬁcance was set at p < 0.05.
RESULTS
BASAL SYNAPTIC TRANSMISSION IS NOT ALTERED 1 WEEK AFTER
ACUTE TREATMENT WITH AN IRREVERSIBLE NMDAR ANTAGONIST
Firstly, possible long-term effects of a single MK801-injection on
basal synaptic transmission were assessed. To this end, experi-
ments in which test-pulse stimulation was monitored for ca. 24 h
prior to, and 1 week after MK801-treatment, were performed.
PS amplitude and fEPSP were analyzed in both conditions. No
differences in PS amplitude or in fEPSP (n = 6, Figures 1A–C)
were found in animals that were injected with MK801 1 week
prior to the experiment, as compared to control baseline.
Thus, MK801 does not elicit long-term effects on basal synaptic
transmission.
A LONG-TERM DISRUPTION OF LTP, WHICH LASTS FOR AT LEAST
4 WEEKS OCCURS FOLLOWING ACUTE TREATMENT WITH AN
IRREVERSIBLE NMDAR ANTAGONIST
One, two, three, or four weeks after an acute injection with
MK801, the ability to express LTP was signiﬁcantly impaired
1 week after MK801-treatment [PS: F(1,6) = 7.960, p < 0.05,
n = 7, Figures 2A,F; fEPSP: F(1,6) = 8.940, p < 0.05, n = 7,
Figures 2B,F]; 2 weeks [PS: F(1, 6) = 10.272, p < 0.05, n = 7,
Figures 2C,F; fEPSP: F(1,6) = 3.047, n.s., n = 7, not shown],
3 weeks [PS: F(1,6) = 7.591, p < 0.05; n = 7, Figures 2D,F;
fEPSP: F(1,6) = 11.306, p < 0.05, n = 7, not shown], and 4 weeks
[PS: F(1,6) = 11.420, p < 0.05, n = 7, Figures 2E,F; fEPSP:
F(1,6) = 7.417, p < 0.05, n = 7, not shown] after treatment
with MK801, LTP was still signiﬁcantly disrupted as compared to
control LTP.
Thus, the MK801-induced impairment in the ability to express
hippocampal LTP lasts for at least 4 weeks.
By contrast, in the control cohort, that was systemically treated
with vehicle, the ability to express LTP was not altered (Figure 3).
ONEWEEK AFTER ACUTE TREATMENTWITH AN IRREVERSIBLE NMDAR
ANTAGONIST, ANIMALS DO NOT DISPLAY ALTERATIONS IN
LOCOMOTOR ACTIVITY OR ANXIETY-RELATED BEHAVIOR IN THE OPEN
FIELD TEST
The total distance moved in the open ﬁeld arena was not differ-
ent between vehicle- (n = 7) and MK801-injected (n = 7) rats
1 week after treatment (Figure 4A). Thus, subsequent behavioral
experiments were not biased by differences in locomotor abilities.
In addition, both groups spent a comparable amount of time in
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FIGURE 1 | Acute treatment with an irreversible NMDAR antagonist
elicits no lasting effects on basal synaptic transmission. Basal synaptic
transmission is unaffected 1 week after MK801-treatment. No differences
in PS amplitude (A) or in fEPSP (B) occur 1 week after a single
MK801-injection (black squares, n = 6) as compared to control baseline
(white squares, n = 6) in response to test-pulse stimulation. Line breaks on
the x -axis indicate change in time-scale. (C) Original analog traces show
ﬁeld potentials evoked from the dentate gyrus during (i) test-pulse
stimulation before MK801-treatment and (ii) test-pulse stimulation 1 week
after MK801-treatment. Vertical scale-bar corresponds to 5 mV, horizontal
scale-bar to 10 ms.
the center of the arena (Figure 4B), indicating that vehicle- and
MK801-treated animals did not differ in anxiety-related behavior
1 week after treatment.
PERFORMANCE IN AN OBJECT RECOGNITION TASK IS PERSISTENTLY
IMPAIRED FOLLOWING ACUTE TREATMENT WITH AN IRREVERSIBLE
NMDAR ANTAGONIST
To exclude that locomotor differences could affect the outcome
of behavior in the memory paradigm, we ﬁrst assessed abso-
lute exploration levels betweenMK801-treated and vehicle-treated
animals (Figures 4C,D). We found no signiﬁcant differences in
absolute exploration levels between the different groups during
the T1 (Figure 4C) where two identical objects were explored
and T2 where a new object was substituted for one of the old
objects (Figure 4D), either 1, 2, 3, or 4 weeks after vehicle or
MK801-treatment.
Control animals demonstrated a signiﬁcant memory perfor-
mance 1, 2, 3, and 4 weeks after vehicle treatment in T2
(Figure 4E). Here, 4 h after T1 one of the now familiar objects
was replaced with a novel object and exploration of both, the old
and new objects, was compared.
Statistical analysis revealed signiﬁcant effects at: 1 week
[t(18) = 4.999, p < 0.0001; n = 10; Figure 4E]; 2 weeks
[t(18) = 5.113, p < 0.0001; n = 10; Figure 4E]; 3 weeks
[t(16) = 4.810, p < 0.0001; n = 9; Figure 4E] and
4 weeks after vehicle-treatment [t(16) = 4.053, p < 0.001; n = 9;
Figure 4E].
By contrast, if rats underwent a single MK801-induced
psychosis-like episode, they showed impaired object recognition
memory during T2 when assessed 1, 2, and 3 weeks after treatment
with MK801, as exploration levels for the new object were not dif-
ferent from those for the old object (Figure 4F). By 4 weeks after a
single MK801-treatment, the animals showed a signiﬁcant mem-
ory performance (t (24) = 2.616, p < 0.05; n = 13; Figure 4F), but
tended to be less able to distinguish the new object from the old
compared to the performance of the control animals. For exam-
ple, control animals explored the new object ca. 70% of the time
4 weeks after vehicle-treatment, whereas MK801-treated animals
explored the new object less than 60% of the time.
CELL NUMBERS WITHIN THE RSC, DG, AND EC DID NOT DIFFER
BETWEEN CONTROLS AND MK801-INJECTED ANIMALS 4 WEEKS
AFTER TREATMENT
MK801 has been reported to induce neurodegeneration at high
concentrations (typically 10 mg/kg) in certain brain areas, pri-
marily in the RSC (Olney et al., 1989). In order to investigate if
our concentration may have caused degenerative effects, we per-
formed cell counts in the RSC, the DG, and the EC. The number of
viable neurons did not differ between MK801- and vehicle-treated
animals in any of the analyzed regions 4 weeks after treatment
(Figures 5B,C).
DISCUSSION
This study shows that acute, single treatment with an irreversible
NMDA receptor antagonist elicits lasting effects on hippocampal
function: bothLTPandobject recognitionmemory are profoundly
impaired, with effects lasting for weeks. This ﬁnding is strik-
ing, as it suggests that NMDA receptor hypofunction occurs as
a consequence of treatment. This may take the form of a lack of
recovery of receptor numbers, but could also derive from changes
in NMDA receptor subunit constellations and /or distributions as
a result of MK801 application. Evidence of the latter, following
subchronic MK801-treatment has been reported (Wang and Gao,
2012). NMDA receptor hypofunction is believed to contribute
to schizophrenia-spectrum disorders including psychosis (Coyle
et al., 2003; Vrajová et al., 2010). Our current observations there-
fore open up the interesting possibility that the cognitive deﬁcits
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FIGURE 2 | Acute treatment with an irreversible NMDAR antagonist
leads to a persistent long-term impairment of LTP in vivo, which lasts for
at least 4 weeks. One week after MK801-treatment, LTP of population spike
amplitude (A) and of fEPSP (B) are signiﬁcantly impaired compared to
control LTP (n = 7). This impairment persists in the second (n = 7) (C), third
(n = 7) (D), and fourth (n = 7) (E) weeks after MK801-treatment (relative
changes in fEPSP responses were equivalent to changes in PS amplitude.
Representative example is shown in Figure 2B). Line breaks on the x -axis
indicate change in time-scale. (F) Original analog traces show ﬁeld potentials
evoked from the dentate gyrus during (i) control LTP and (ii) LTP elicited
1 week after a single systemic MK801-treatment, (iii) LTP induced 2 weeks
after MK801-treatment, (iv) LTP elicited 3 weeks after MK801-treatment and
(v) LTP induced 4 weeks after MK801-treatment. Vertical scale-bar
corresponds to 5 mV, horizontal scale-bar to 10 ms.
that accompany schizophrenia in psychotic patients may derive
from NMDA receptor dysfunction and an associated a loss of
hippocampus-dependent synaptic plasticity and learning.
Irreversible uncompetitive NMDAR-antagonists induce psy-
chotic symptoms in healthy humans and exacerbate symptoms
of schizophrenic patients (Krystal et al., 1994; Lahti et al., 2001).
Out of all known NMDAR-antagonists, MK801 (dizocilpine) has
the highest potency for the phencyclidine (PCP) binding site and
strongest psychotomimetic properties (Kornhuber and Weller,
1997). Immediately following treatment with the irreversible
NMDA receptor antagonist, MK801 rodents exhibit symptoms
of acute psychosis (Wöhrl et al., 2007; Manahan-Vaughan et al.,
2008a,b). Recovery is rapid but is accompanied by plasticity
deﬁcits, and it is tempting to speculate that this state emulates
ﬁrst-episode psychosis that typically heralds the onset of chronic
schizophrenia in humans (McGlashan, 2006; Alvarez-Jimenez
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FIGURE 3 | A single vehicle injection does not change the ability
to express LTP over time. One (n = 6) (A), 2 (n = 6) (B), 3 (n = 5) (C)
and 4 (n = 6) (D) weeks after a single vehicle injection, LTP of PS
amplitude (black squares) and of fEPSP (data not shown) is not different
from control LTP (white squares). Line breaks on the x-axis indicate
change in time-scale. (E) Original analog traces show ﬁeld potentials
evoked from the dentate gyrus during (i) control LTP and (ii) LTP
elicited 1 week after a single systemic vehicle treatment, (iii) LTP
induced 1 weeks after vehicle treatment, (iv) LTP elicited 3 weeks
after vehicle treatment and (v) LTP induced 4 weeks after vehicle
treatment. Vertical scale-bar corresponds to 5 mV, horizontal scale-bar
to 10 ms.
et al., 2011). Anunansweredquestion iswhatmechanismsunderlie
the transition from ﬁrst-episode psychosis to chronic schizophre-
nia? Our results reveal that a single psychosis-like episode in
rodents produces persistent long-term consequences, in the areas
of cognition and synaptic plasticity. We hypothesize that these
enduring cellular consequences might mirror an increased over-
all vulnerability of the brain after acute psychosis, that in turn
reﬂects physiological adaptations that enable the establishment of
the disease.
In our behavioral experiments, long-term deﬁcits in object
recognition memory were detected for at least 3 weeks after
acute treatment with MK801. The ORT is widely used for
assessment of memory deﬁcits in animal models of schizophre-
nia (de Lima et al., 2005; Goulart et al., 2010; Snigdha et al.,
2010). The rationale behind the use of this behavioral pro-
cedure is the fact that schizophrenic patients show profound
deﬁcits in the recognition and recall of non-verbal stim-
uli (Schretlen et al., 2007). Moreover, unlike other animal
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FIGURE 4 | Acute treatment with an irreversible NMDA antagonist
disrupts object recognition memory for several weeks after
treatment. Locomotor activity and anxiety-related behavior are not
affected. (A) Locomotor activity is not different between rats treated with
vehicle (white column, n = 7) or MK801 (gray column, n = 7) 1 week prior to
the experiment. (B) Vehicle (white column, n = 7) and MK801-injected rats
(gray column, n = 7) spend an equal % of time in the center of the open ﬁeld
arena one week after treatment. (C,D)Total exploration times do not differ
signiﬁcantly between the vehicle- (white column) and MK801-treated (gray
column) rats duringT1 (ﬁrst exposure to two new objects) and duringT2
(exposure 4 h later to one familiar object and one novel object). (E) Control
rats remember the familiar object after an interval of 4 h, as indicated by
signiﬁcantly longer exploration of the new (white column) as compared
to the old (gray column) object at any time-point (n = 10 in ﬁrst week,
n = 10 in second week, n = 9 in third week, n = 9 in fourth week). (F) A
single MK801-injection leads to a long-term impairment in object recognition
memory performance which lasts for at least 3 weeks after treatment. 1
(n = 11), 2 (n = 13) or 3 weeks (n = 12) after an acute MK801-induced
psychosis-related event, rats are not able to distinguish the familiar (gray
column) from the new (white column) object, as indicated by approximately
equal exploration times. In the 4 week (n = 13) after MK801-treatment
memory performance is signiﬁcant but still tends to be poorer than the
performance seen in controls. Values represent means ± S.E.M.; *p < 0.05,
**p < 0.001, ***p < 0.0001.
memory tests (e.g., radial maze, Morris water maze, or T-
maze), the ORT does not require motivational factors such
as e.g., food reward or escape from water. It is purely based
on the intrinsic motivation of the rodent, which makes it
more valid in terms of its comparability to human memory
tests. It has been already shown that rats treated with an
irreversible NMDAR-antagonist display impaired performance
in the ORT immediately after treatment (Nilsson et al., 2007;
van der Staay et al., 2011). However, the duration of this
effect has not yet been investigated systematically over such
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FIGURE 5 | Neuron numbers do not differ in the retrosplenial
cortex (RSC), dentate gyrus (DG), and entorhinal cortex (EC) when
tissue from vehicle- and MK801-injected animals is compared
4 weeks after treatment. (A) Representative example of the section
plane analysed (−5.3 respect to Bregma) with the predeﬁned regions of
interest (ROIs) of the same size (750 μm × 1000 μm) in the left and
right hemispheres. (B,C) Average cell numbers do not differ between
controls and MK801-treated animals 4 weeks after injection. RSC,
retrosplenial cortex; DG, dentate gyrus; EC, entorhinal cortex; r, right;
l, left.
a long period. The fact that the cognitive symptoms were
speciﬁcally and persistently affected after MK801-treatment is
in line with the widespread belief that cognitive deﬁcits, such
as impairments in declarative memory, dominate as factors
leading to poor functional outcomes in schizophrenia (Stone and
Hsi, 2011).
Anothermajor ﬁnding of our study is the fact that hippocampal
synaptic plasticity is the most prominently and potently affected
parameter after acuteMK801-treatment and is therefore putatively
the central long-term consequence of NMDA receptor hypofunc-
tion. Our results show that the inability to express normal LTP
in the hippocampus persists for at least 4 weeks after a single
MK801-treatment. Hippocampal LTP is a widely studied cellu-
lar phenomenon, comprising strengthening of synaptic efﬁcacy
after repetitive stimulation, which is believed to underlie learn-
ing and memory (Bliss and Collingridge, 1993). The concept of
synaptic plasticity has been linked to schizophrenia pathology
in many contemporary theoretical considerations (Peled, 2005;
McGlashan, 2006). For instance, the question, as to whether the
process mediating consequences of active psychosis might com-
prise neurotoxicity or rather impaired synaptic plasticity, was
introduced just a few years ago (McGlashan, 2006). However,
as neuronal death and reduction in neuron numbers has not
been convincingly demonstrated in schizophrenic post-mortem
tissue (Harrison, 1999), whereas reduced spine densities (Garey
et al., 1998; Glantz and Lewis, 2000) were reported, the synaptic
plasticity hypothesis has become regarded as the more plausible
one. In addition, many of the identiﬁed schizophrenia suscep-
tibility genes have been linked to synaptic plasticity (Harrison
and Weinberger, 2005). In line with these ﬁndings, our study
experimentally supports the assumption that impaired ability to
express synaptic plasticity is the main pathological factor under-
lying acute psychosis. Furthermore, we hypothesize that impaired
synaptic plasticity is the cellular substrate of increased vulner-
ability for further psychotic episodes caused by future stressful
events.
Although the impairment in the ability to express LTP correlates
strongly with deﬁcits in memory, it outlasts the effects on mem-
ory observed in this study, which is probably due to the relative
insensitivity of the behavioral test procedure. In any case, synap-
tic plasticity seems to be the most representative measurement of
persistent long-term effects after a single psychotic episode. There-
fore it might be the most valuable and valid parameter for testing
potential new therapeutics in preclinical settings. However, the
extrapolation from animal to human should always be considered
with reservation, especially, in psychiatric research. Of course,
the question as to whether synaptic plasticity is also affected in
humans in a long-term manner following ﬁrst-episode psychosis
remains speculative. Nevertheless, recent evidence indicates that
LTP-like facilitation is indeed inducible in humans via e.g., TMS
(Korchounov and Ziemann, 2011) and that LTP may be disrupted
in schizophrenic patients, albeit in another cortical area (Frantseva
et al., 2008).
In any case, the mechanism underlying this persistent effect
remains to be discovered. We hypothesize that a single treatment
with MK801 induces a long-lasting physiological change of the
whole system which will probably be reﬂected by an enduring
NMDAR-hypofunction. This hypofunction does not necessarily
relate to the NMDAR numbers, as MK801 (bound to NMDAR)
will be metabolized from the brain (Wegener et al., 2011) and new
NMDARs will be inserted into the membrane to replace those
lost. It may also result from altered NMDAR subunit expres-
sion, or from a dysfunctional molecule up- or downstream to the
NMDAR itself. These possibilities should be the subject of future
studies.
MK801 at high concentrations can induce irreversible damage
in a brain area and gender-speciﬁcmannerwith theRSC in females
being the most vulnerable (Olney et al., 1989; Bender et al., 2010).
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Speciﬁcally, at the concentration used in this study (5mg/kg), sev-
eral studies found neurotoxic effects in certain brain areas (Fix
et al., 1993; Farber et al., 1995), others found partly transient
damage (Horváth et al., 1997) or even failed to detect any mor-
phological changes at all after MK801-treatment (Wöhrl et al.,
2007). Our quantitative analysis of viable cell numbers within
the DG, EC, and RSC revealed no neurotoxic effects 4 weeks after
MK801-treatment as compared to controls. Thus, either MK801
did not induce degeneration at the concentration used, or pos-
sible MK801-induced effects on cell numbers were transient and
therefore undetectable 4 weeks after treatment. Hence, we can-
not completely rule out the possibility that potential neurotoxic
effects elsewhere in thebrainmay contribute to the effects observed
in this study. However under the conditions used, we did not
ﬁnd evidence of brain damage and therefore it is unlikely that
neurotoxicity played a role in our results.
Pharmacological animal models of psychosis are usually uti-
lized for assessment of potential therapeutic effects of new
compounds. The model of acute psychosis used in this work has
already been implemented in suchpreclinical studies. For example,
1 week after MK801-treatment the deﬁcit in LTP can be pre-
vented by different substances such as an inhibitor of the glycine
transporter-1 (GlyT1) or inhibition of the phosphodiesterase-4
(PDE4) (Manahan-Vaughan et al., 2008b; Wiescholleck and
Manahan-Vaughan, 2012). The current ﬁnding, that in this model
the deﬁcits in LTP and in object recognition memory persist for
weeks, opens up the possibility of exploration of the duration of
the therapeutic effects of test compounds.
Finally, in linewithnumerous previous studies (Harrison,2004;
Heckers and Konradi, 2010; Tamminga et al., 2010) this ﬁnding
supports a pivotal role of the hippocampus in the pathology of
schizophrenia-spectrumdisorders. Of note, recently, hippocampal
LTP has been shown to profoundly inﬂuence prefrontal cor-
tex activation (Canals et al., 2009) – hence, it is thinkable that
MK801-induced long-term impairment in synaptic plasticity in
the hippocampus will affect and spread to other schizophrenia-
relevant brain structures. A graph theory model of NMDA
receptor hypofunction in schizophrenia predicts that this may
indeed be the case (Dawson et al., 2012).
CONCLUSION
Taken together, our data suggest that an acute psychosis-like
episode, induced by a single treatment with MK801, produces
long-term effects on the synaptic and cognitive behavioral lev-
els. Thus, this might reﬂect a mechanism by which an acute
psychotic event supports the development of chronic illness. As
the inability to express normal synaptic plasticity persists for
the longest period, we propose that deﬁcits in hippocampal LTP
may comprise one of the cellular substrates leading to increased
vulnerability of the brain towards developing further psychotic
episodes.
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